# Pediatrics / Children: Topic Summary Hub

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/topic-pediatrics-children/
> **Published:** 2026-09-04T23:08:15-04:00 | **Last Modified / Clinically Audited:** 2026-10-17T11:42:20-04:00
> **Clinical Summary:** CED CLINICAL TOPIC SUMMARY HUB Pediatrics / Children Welcome to the authoritative CED Clinic topic summary hub for Pediatrics / Children. Below is our comprehensive repository of peer-reviewed clinical guides, diagnostic flowcharts, pharmacological pathways, patient FAQs, and scientific reference data. 🔍 CED Perspective Lens: Pediatrics / Children Dr. Benjamin Caplan, MD Pediatrics / Children represents [&hellip;]

---

CED CLINICAL TOPIC SUMMARY HUB
 

## Pediatrics / Children

 

Welcome to the authoritative CED Clinic topic summary hub for **Pediatrics / Children**. Below is our comprehensive repository of peer-reviewed clinical guides, diagnostic flowcharts, pharmacological pathways, patient FAQs, and scientific reference data.

 

 
 
 
 

#### 🔍 CED Perspective Lens: Pediatrics / Children

 Dr. Benjamin Caplan, MD
 
 

Pediatrics / Children represents a fundamental pillar in medical endocannabinoid therapy. Every guide in this hub synthesizes peer-reviewed evidence, clinical dosing strategies, and physiological mechanism maps curated specifically for patient care and clinical guidance.

 

 
 
 

## 📚 Clinical Resources & Guides (1 Full Guides)

 

 
 
 
 Resource #1
 

### Children and Medical Cannabis: Understanding Therapeutic Potentials and Precautions

 

In recent years, medical cannabis has emerged as a versatile treatment option for a wide range of conditions. Its utility in pediatric care has generated significant interest,…

 
 
 [Read Complete Article & View Charts →](https://cedclinic.com/children-and-medical-cannabis-understanding-therapeutic-potentials-and-precautions/)
 
 
 

 
 
 
 
 Pediatric Medicine Feature
 

### Clinical Video Guide: Pediatric Cannabinoid Safety & Protocols

 

Dr. Caplan explores zero-intoxication pediatric therapies, clinical monitoring guidelines, and certified pure formulations.

 
 
 [🎬 Watch Masterclass Hub ↗](/videos/autism-pediatric-cannabinoid-therapy/)
 [⚡ 137 Video Reels ↗](/videos/tiktok-clinical-education/)
 
 
 
 
 
 
 
 
 
 
 
 
 
 Featured Masterclass
 
 [▶](/videos/autism-pediatric-cannabinoid-therapy/)
 
 
 
 

#### Pediatric Autism & Neurodevelopment Hub

 

Televised clinical evidence and physician oversight in non-intoxicating pediatric cannabinoid medicine.

 
 
 
 
 [Explore Dedicated Hub, Video & Transcripts →](/videos/autism-pediatric-cannabinoid-therapy/)
 
 

 
 
 
 
 
 
 
 60-Second Video Lesson
 
 [▶](https://www.tiktok.com/@drbenjamincaplan/video/7635012573192113438)
 

 
 

#### Cannabis and Autism: The Question Medicine Keeps Avoiding

 

Why real-world clinical data and physician monitoring replace silence with evidence.

 
 
 
 
 [♬ Watch Lesson on TikTok ↗](https://www.tiktok.com/@drbenjamincaplan/video/7635012573192113438)
 |
 [YouTube Shorts ↗](/videos/shorts/)

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
